Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.010
+0.010 (0.25%)
At close: Oct 5, 2026, 4:00 PM EDT
4.010
0.00 (0.00%)
After-hours: Oct 5, 2026, 4:10 PM EDT
Camp4 Therapeutics Revenue
Camp4 Therapeutics had revenue of $1.78M in the quarter ending June 30, 2026, with 18.84% growth. This brings the company's revenue in the last twelve months to $4.22M, up 40.21% year-over-year. In the year 2025, Camp4 Therapeutics had annual revenue of $3.50M with 436.50% growth.
Revenue (ttm)
$4.22M
Revenue Growth
+40.21%
P/S Ratio
59.91
Revenue / Employee
$87,833
Employees
48
Market Cap
251.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.50M | 2.85M | 436.50% |
| Dec 31, 2024 | 652.00K | 302.00K | 86.29% |
| Dec 31, 2023 | 350.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
CAMP News
- 10 hours ago - Camp4 Therapeutics initiated with an Outperform at Oppenheimer - TheFly
- 6 days ago - Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan - TheFly
- 7 days ago - Camp4 Therapeutics Transcript: Analyst Day 2026 - Transcripts
- 7 days ago - Camp4 Therapeutics Slides: FY 2026 - Filings
- 25 days ago - CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder - GlobeNewsWire
- 26 days ago - Camp4 Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 27 days ago - CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 - GlobeNewsWire
- 4 weeks ago - CAMP4 to Participate in Upcoming Investor Conferences - GlobeNewsWire